Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
Vestal Point Capital
On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. Based on the notification, Vestal Point Capital holds 1,809,843 voting rights, representing 4.84% of the total number of voting rights on May 21, 2025 (37,427,265).
The notification dated May 27, 2025 contains the following information:
| A) Voting rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
| Ryan Wilder | 0 | 0 | 0 | 0.00% | 0.00% |
| Vestal Point Capital, LLC | 0 | 0 | 0 | 0.00% | 0.00% |
| Vestal Point Capital, LP | 3,000,688 | 1,809,843 | 0 | 4.84% | 0.00% |
| Subtotal | 3,000,688 | 1,809,843 | 4.84% | ||
| TOTAL | 1,809,843 | 0 | 4.84% | 0.00% | |
Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$4.57 |
| Daily Change: | 0.03 0.66 |
| Daily Volume: | 111,107 |
| Market Cap: | US$196.650M |
November 13, 2025 November 13, 2025 September 23, 2025 September 02, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load